Hepatitis B and HIV-1 2019 IAS Cure Forum: lessons and benefits from interdisciplinary research.

J Virus Erad

Wits/SAMRC Antiviral Gene Therapy Research Unit, School of Pathology, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.

Published: November 2019

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6844409PMC
http://dx.doi.org/10.1016/S2055-6640(20)30027-3DOI Listing

Publication Analysis

Top Keywords

hepatitis hiv-1
4
hiv-1 2019
4
2019 ias
4
ias cure
4
cure forum
4
forum lessons
4
lessons benefits
4
benefits interdisciplinary
4
hepatitis
1
0
1

Similar Publications

Background: Nonenveloped viruses, such as hepatitis A virus (HAV) and parvovirus B19 (B19V), are not inactivated by detergents and solvents commonly used to manufacture plasma derivatives. Cases of transfusion-transmitted HAV and B19V have already been described in several countries. This study aimed to determine the incidence of HAV and B19V asymptomatic infections in blood donors from Rio de Janeiro and evaluate the residual risk of transmission to blood derivative recipients.

View Article and Find Full Text PDF

Background: Due to the unique geographical and climatic conditions in Nagqu (Tibet), the blood station laboratory was only fully established and accredited by 2020. This study validated the performance of the laboratory's blood screening system and analyzed recent trends in blood donation and screening effectiveness.

Methods: Various serum samples were used to assess the performance of hepatitis B, hepatitis C, HIV, and syphilis tests, both serological and nucleic acid tests.

View Article and Find Full Text PDF

We investigated several small viral proteins that reside and function in cellular membranes. These proteins belong to the viroporin family because they assemble into ion-conducting oligomers. However, despite forming similar oligomeric structures with analogous functions, these proteins have diverse amino acid sequences.

View Article and Find Full Text PDF

The HIV integrase inhibitor, dolutegravir (DTG), in the absence of eliciting integrase (int) resistance, has been reported to select mutations in the virus 3'-polypurine tract (3'-PPT) adjacent to the 3'-LTR U3. An analog of DTG, cabotegravir (CAB), has a high genetic barrier to drug resistance and is used in formulations for treatment and long-acting pre-exposure prophylaxis. We examined whether mutations observed for DTG would emerge in vitro with CAB.

View Article and Find Full Text PDF

Antiviral Agents: Structural Basis of Action and Rational Design.

Subcell Biochem

December 2024

Department of Biomedical Sciences, Universidad de Alcalá, Alcalá de Henares, Madrid, Spain.

During the last forty years, significant progress has been made in the development of novel antiviral drugs, mainly crystallizing in the establishment of potent antiretroviral therapies and the approval of drugs eradicating hepatitis C virus infection. Although major targets of antiviral intervention involve intracellular processes required for the synthesis of viral proteins and nucleic acids, a number of inhibitors blocking virus assembly, budding, maturation, entry, or uncoating act on virions or viral capsids. In this review, we focus on the drug discovery process while presenting the currently used methodologies to identify novel antiviral drugs by means of computer-based approaches.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!